Literature DB >> 350367

Immunologic findings, thrombocytopenia and disease activity in lupus nephritis.

W F Clark, A L Linton, P E Cordy, P E Keown, R C Lohmann, R M Lindsay.   

Abstract

Twenty patients with nephritis due to systemic lupus erythematosus were followed up for a mean of 34 months after renal biopsy with serial determinations of total serum complement and C3 and C4 concentrations, binding of deoxyribonucleic acid (DNA), antinuclear antibody pattern and platelet count. There were 25 episodes of nonhematologic observed disease activity in 16 of the 20 patients; elevated DNA binding and thrombocytopenia correlated well with these episodes. The mean platelet count during episodes of observed disease activity was 96 +/- 42 X 10(9)/L, which was significantly different from the mean count of 248 +/- 90 X 10(9)/L during disease quiescence. The proportion of false-positive results with the immunologic tests varied from 25% to 67% and with platelet counts it was 11%. It is suggested that thrombocytopenia may be a simple and accurate index of disease activity in lupus nephritis.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 350367      PMCID: PMC1818379     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


  22 in total

1.  Immunologic studies of systemic lupus erythematosus. II. Variations of nucleoprotein-reactive gamma globulin and hemolytic serum complement levels with disease activity.

Authors:  A S TOWNES; C R STEWART; A G OSLER
Journal:  Bull Johns Hopkins Hosp       Date:  1963-04

2.  Systemic lupus erythematosus: review of the literature and clinical analysis of 138 cases.

Authors:  A M HARVEY; L E SHULMAN; P A TUMULTY; C L CONLEY; E H SCHOENRICH
Journal:  Medicine (Baltimore)       Date:  1954-12       Impact factor: 1.889

3.  The platelet as a mediator of tissue damage in immune complex glomerulonephritis.

Authors:  W F Clark; M Friesen; A L Linton; R M Lindsay
Journal:  Clin Nephrol       Date:  1976-07       Impact factor: 0.975

4.  Estimating prognosis in systemic lupus erythematosus.

Authors:  J F Fries; S Weyl; H R Holman
Journal:  Am J Med       Date:  1974-10       Impact factor: 4.965

5.  Favorable outcome in diffuse proliferative glomerulonephritis of systemic lupus erythematosus.

Authors:  W V Epstein; H Grausz
Journal:  Arthritis Rheum       Date:  1974 Mar-Apr

6.  The clinical significance of antinuclear antibodies.

Authors:  E M Tan; J D Northway; J L Pinnas
Journal:  Postgrad Med       Date:  1973-11       Impact factor: 3.840

7.  Comparison of azathioprine, prednisone, and heparin alone or combined in treating lupus nephritis.

Authors:  R Cade; G Spooner; E Schlein; M Pickering; A DeQuesada; A Holcomb; L Juncos; G Richard; D Shires; D Levin; R Hackett; J Free; R Hunt; M Fregly
Journal:  Nephron       Date:  1973       Impact factor: 2.847

8.  Measurement of serum DNA-binding activity in systemic lupus erythematosus.

Authors:  T Pincus; P H Schur; J A Rose; J L Decker; N Talal
Journal:  N Engl J Med       Date:  1969-09-25       Impact factor: 91.245

9.  Cyclophosphamide or azathioprine in lupus glomerulonephritis. A controlled trial: results at 28 months.

Authors:  J L Decker; J H Klippel; P H Plotz; A D Steinberg
Journal:  Ann Intern Med       Date:  1975-11       Impact factor: 25.391

10.  Hematologic aspects of systemic lupus erythematosus. Current concepts.

Authors:  D R Budman; A D Steinberg
Journal:  Ann Intern Med       Date:  1977-02       Impact factor: 25.391

View more
  1 in total

1.  Monthly plasmapheresis for systemic lupus erythematosus with diffuse proliferative glomerulonephritis: a pilot study.

Authors:  W F Clark; R M Lindsay; D C Cattran; W B Chodirker; C C Barnes; A L Linton
Journal:  Can Med Assoc J       Date:  1981-07-15       Impact factor: 8.262

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.